Cargando…

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression

Emerging studies have shown that the expression of AR splice variants (ARv) lacking ligand-binding domain is associated with castrate-resistant prostate cancer (CRPC) and higher risk of tumor metastasis and recurrence. Nuclear export protein XPO1 regulates the nuclear localization of many proteins i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aboukameel, Amro, Muqbil, Irfana, Baloglu, Erkan, Senapedis, William, Landesman, Yosef, Argueta, Christian, Kauffman, Michael, Chang, Hua, Kashyap, Trinayan, Shacham, Sharon, Neggers, Jasper E., Daelemans, Dirk, Heath, Elisabeth I., Azmi, Asfar S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219671/ https://www.ncbi.nlm.nih.gov/pubmed/30450161 http://dx.doi.org/10.18632/oncotarget.26239

Ejemplares similares

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
por: Khan, Husain Yar, et al.
Publicado: (2019)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
por: Muqbil, Irfana, et al.
Publicado: (2019)

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
por: Mpilla, Gabriel, et al.
Publicado: (2019)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

Cancer cachexia research: coming of age
por: Muqbil, Irfana, et al.
Publicado: (2023)

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer
por: Gao, Jiankun, et al.
Publicado: (2014)

Nuclear Export Inhibition for Pancreatic Cancer Therapy
por: Muqbil, Irfana, et al.
Publicado: (2018)

PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma
por: Khan, Husain Yar, et al.
Publicado: (2021)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
por: Rane, Chetan, et al.
Publicado: (2017)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
por: Muqbil, Irfana, et al.
Publicado: (2011)

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma
por: Diab, Maria, et al.
Publicado: (2016)

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
por: Walker, Christopher J., et al.
Publicado: (2022)

Nucleo-cytoplasmic transport as a therapeutic target of cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes
por: Neggers, Jasper Edgar, et al.
Publicado: (2018)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis
por: Muqbil, Irfana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0sf4rfh49v35uk4v94pkhehkh6